Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Non-Current Assets (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Non-Current Assets data on record, last reported at $18.0 million in Q3 2023.

  • For Q3 2023, Non-Current Assets fell 48.82% year-over-year to $18.0 million; the TTM value through Sep 2023 reached $244.3 million, down 27.13%, while the annual FY2022 figure was $86.6 million, 38.38% down from the prior year.
  • Non-Current Assets reached $18.0 million in Q3 2023 per CGEM's latest filing, down from $23.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $140.6 million in Q4 2021 and bottomed at $2.4 million in Q4 2020.
  • Average Non-Current Assets over 4 years is $71.6 million, with a median of $65.5 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: skyrocketed 5686.87% in 2021, then tumbled 71.77% in 2022.
  • A 4-year view of Non-Current Assets shows it stood at $2.4 million in 2020, then surged by 5686.87% to $140.6 million in 2021, then crashed by 38.38% to $86.6 million in 2022, then crashed by 79.23% to $18.0 million in 2023.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $18.0 million in Q3 2023, $23.7 million in Q2 2023, and $116.0 million in Q1 2023.